Hypertension Clinical Trial
Official title:
Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19
Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.
SARS-Cov-2 infection is characterized by a varied clinical course, from asymptomatic to
severe respiratory failure in the course of pneumonia, which can be fatal. There are reports
in the literature regarding the relationship between the course of an acute respiratory
disease syndrome caused by SARS-CoV-2 virus infection (Coronavirus 2019, COVID-19) and the
history of cardiovascular diseases (CVD), including hypertension. It is postulated that the
shared element of the pathogenesis of CVD, hypertension and COVID-19 is the renin-angiotensin
system and one of its elements, the angiotensin converting enzyme 2 (ACE2). It has been
postulated by some authors that in the course of hypertension and antihypertensive treatment
with renin-angiotensin system inhibitors, there may be an upregulation of ACE2, which in turn
may be related to a higher risk of more severe course of COVID-19. On the other hand there is
also data the renin-angiotensin system inhibitors by increasing ACE2 concentration may be
protective in the course of severe pneumonia.
The study undertaken by the National Institute of Cardiology aims to assess the safety of the
cardiovascular drugs in relation to the occurrence of complications during hospitalization in
patients with CVD and COVID-19 infection. The study is being conducted by Polish-German
collaboration and was initiated by prof Reinhold Kreutz from Institute of Clinical
Pharmacology and Toxicology, Charite, Berlin, Germany and team from National Institute of
Cardiology lead by prof. Andrzej Januszewicz and prof. Tomasz Hryniewiecki, Director of the
National Institute of Cardiology.
Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
After the hospitalization, a short questionnaire will be completed, including
pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission,
the course, complication and the duration of hospitalization. The questionnaire will be
available in paper form and on-line.
It will also be planned to include control groups from the official databases: 1) patients
with SARS-CoV-2 infection not requiring hospitalization, and 2) structure-matched and
co-existing disease matched control group from the general population.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
| Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
| Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
| Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
| Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
| Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |